Windlas Biotech Ltd Stock Price Today (NSE: WINDLAS)
Fundamental Score
Windlas Biotech Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Windlas Biotech Ltd share price today is ₹736.75, down 1.94% on NSE/BSE as of 30 March 2026. Windlas Biotech Ltd (WINDLAS) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.66K (Cr). The 52-week high for WINDLAS share price is ₹1140.00 and the 52-week low is ₹697.40. At a P/E ratio of 24.62x, WINDLAS is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 12.76% and a debt-to-equity ratio of 0.06.
Windlas Biotech Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Windlas Biotech Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Windlas Biotech Share Price: A Financial Analysis for Growth
One key trend in the pharmaceutical sector is the growing demand for contract development and manufacturing organizations (CDMOs) driven by large pharma companies seeking to optimize costs and focus on core competencies. This analysis provides an observational perspective on Windlas Biotech share price performance and financial health. Currently trading at ₹854.0499877929688, with a PE ratio of 24.62, Windlas Biotech operates within a competitive landscape that includes companies like Mankind Pharma Ltd, Smruthi Organics Ltd, and Balaxi Pharmaceuticals Ltd.
Comparing Windlas Biotech to its peers, particularly
Mankind Pharma Ltd, differences in management quality and strategic direction could influence future growth trajectories. While it's outside the scope of this limited analysis, a deep dive into management's capital allocation skills and past track record is crucial for assessing long-term value creation. For instance, comparing it with Mankind Pharma's strong track record for strategic branding, the management of Windlas Biotech may have a different strategy.Windlas Biotech's Return on Capital Employed (ROCE) of 16.96% is a vital metric. ROCE reflects the efficiency with which the company generates profits from its capital base. A consistently high ROCE, like 16.96%, can be a powerful indicator of a developing economic moat. This suggests that Windlas Biotech may possess certain competitive advantages, such as specialized manufacturing capabilities or strong client relationships, that allow it to earn above-average returns. These advantages, if sustainable, could provide a buffer against competitive pressures.
This analysis of Windlas Biotech share price forms part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra. This provides a framework to assess the company’s growth potential. Please note that this is an observational analysis and should not be interpreted as investment advice. Further due diligence is recommended before making any investment decisions.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Windlas Biotech Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of WINDLAS across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Excellent ROCE Performance (16.96%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 24.62 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (18.93%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (18.24% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (30.32% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.06)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (19.07x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹78.58 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (61.99%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Weak Earnings Growth (2.83% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Windlas Biotech Ltd Financial Statements
Comprehensive financial data for Windlas Biotech Ltd including income statement, balance sheet and cash flow
About WINDLAS (Windlas Biotech Ltd)
Windlas Biotech Ltd is a dynamic pharmaceutical company deeply rooted in innovation and quality. Specializing in contract development and manufacturing, Windlas serves as a trusted... partner for pharmaceutical companies seeking expertise in formulation development, manufacturing excellence, and comprehensive regulatory support. The company distinguishes itself through a commitment to cutting-edge technologies and a highly skilled workforce, enabling the production of complex and specialized pharmaceutical products. Windlas is driven by a desire to meet the evolving needs of its clients and contribute to advancements in healthcare, constantly striving to deliver superior products that meet stringent quality standards and regulatory requirements. With a customer-centric approach and a focus on building lasting partnerships, Windlas is positioned as a leading player in the pharmaceutical manufacturing landscape. The company's core strength lies in its diversified product portfolio and its ability to handle complex formulations. Windlas offers a broad range of manufacturing capabilities, including solid oral dosages, modified-release formulations, and specialized dosage forms. They cater to a wide array of therapeutic areas, addressing diverse healthcare needs through their innovative product offerings. Windlas emphasizes research and development, consistently seeking to enhance its manufacturing processes, expand its product range, and develop novel drug delivery systems. This commitment to continuous improvement enables them to offer customized solutions that meet the specific requirements of each client, ensuring product differentiation and market success. Windlas's reputation is built on a foundation of unwavering adherence to international quality standards and regulatory compliance. The company's state-of-the-art manufacturing facilities are equipped with the latest technologies and are meticulously maintained to ensure optimal performance and product integrity. Windlas places a strong emphasis on data integrity, transparency, and ethical business practices. By maintaining the highest standards of quality and compliance, Windlas fosters trust among its clients, regulators, and stakeholders. The company's dedication to quality and regulatory excellence is paramount, underpinning its commitment to delivering safe, effective, and reliable pharmaceutical products to patients worldwide.
Company Details
Key Leadership
Corporate Events
WINDLAS Share Price: Frequently Asked Questions
What is the current share price of Windlas Biotech Ltd (WINDLAS)?
As of 30 Mar 2026, 12:02 pm IST, Windlas Biotech Ltd share price is ₹736.75. The WINDLAS stock has a market capitalisation of ₹1.66K (Cr) on NSE/BSE.
Is WINDLAS share price Overvalued or Undervalued?
WINDLAS share price is currently trading at a P/E ratio of 24.62x, compared to the industry average of 31.77x. Based on this relative valuation, the Windlas Biotech Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of WINDLAS share price?
The 52-week high of WINDLAS share price is ₹1140.00 and the 52-week low is ₹697.40. These values are updated daily from NSE/BSE price data.
What factors affect the Windlas Biotech Ltd share price?
Key factors influencing WINDLAS share price include quarterly earnings growth (Sales Growth: 18.93%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Windlas Biotech Ltd a good stock for long-term investment?
Windlas Biotech Ltd shows a 5-year Profit Growth of 30.32% and an ROE of 12.76%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.06 before investing in WINDLAS shares.
How does Windlas Biotech Ltd compare with its industry peers?
Windlas Biotech Ltd competes with major peers in the Pharmaceuticals. Investors should compare WINDLAS share price P/E of 24.62x and ROE of 12.76% against the industry averages to determine competitive standing.
What is the P/E ratio of WINDLAS and what does it mean?
WINDLAS share price has a P/E ratio of 24.62x compared to the industry average of 31.77x. Investors pay ₹25 for every ₹1 of annual earnings.
How is WINDLAS performing according to Bull Run's analysis?
WINDLAS has a Bull Run fundamental score of 62.1/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does WINDLAS belong to?
WINDLAS operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Windlas Biotech Ltd share price.
What is Return on Equity (ROE) and why is it important for WINDLAS?
WINDLAS has an ROE of 12.76%, which shows decent profitability but room for improvement. ROE measures how efficiently Windlas Biotech Ltd generates profits from shareholders capital.
How is WINDLAS debt-to-equity ratio and what does it indicate?
WINDLAS has a debt-to-equity ratio of 0.06, which indicates conservative financing with low financial risk.
What is WINDLAS dividend yield and is it a good dividend stock?
WINDLAS offers a dividend yield of 0.74%, meaning you receive ₹0.74 annual dividend for every ₹100 invested in Windlas Biotech Ltd shares.
How has WINDLAS share price grown over the past 5 years?
WINDLAS has achieved 5-year growth rates of: Sales Growth 18.24%, Profit Growth 30.32%, and EPS Growth 2.83%.
What is the promoter holding in WINDLAS and why does it matter?
Promoters hold 61.99% of WINDLAS shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Windlas Biotech Ltd.
What is WINDLAS market capitalisation category?
WINDLAS has a market capitalisation of ₹1658 crores, placing it in the Small-cap category.
How volatile is WINDLAS stock?
WINDLAS has a beta of N/A. A beta > 1 suggests the Windlas Biotech Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is WINDLAS operating profit margin trend?
WINDLAS has a 5-year average Operating Profit Margin (OPM) of 12.13%, indicating the company's operational efficiency.
How is WINDLAS quarterly performance?
Recent quarterly performance shows Windlas Biotech Ltd YoY Sales Growth of 18.93% and YoY Profit Growth of 13.67%.
What is the institutional holding pattern in WINDLAS?
WINDLAS has FII holding of 1.11% and DII holding of 11.44%. Significant institutional holding often suggests professional confidence in the Windlas Biotech Ltd stock.